AVN 211

Drug Profile

AVN 211

Alternative Names: AVN-211; CD-008-0173

Latest Information Update: 17 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemDiv
  • Developer Avineuro Pharmaceuticals
  • Class Antidementias; Antipsychotics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Schizophrenia
  • Clinical Phase Unknown Alzheimer's disease
  • Discontinued Anxiety disorders

Most Recent Events

  • 14 Aug 2015 Phase-II development is ongoing for Schizophrenia in USA
  • 16 Jul 2015 Avineuro plans a trial for Alzheimer's disease in USA
  • 16 Jul 2015 Avineuro Pharmaceuticals completes a phase II trial in Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top